• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

托吡酯、安非他酮和纳曲酮单独或联合对肥胖大鼠皮下脂肪组织的影响。

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats.

机构信息

Centro Universitário FMABC, Santo André, SP, Brazil.

出版信息

Einstein (Sao Paulo). 2022 May 30;20:eAO5587. doi: 10.31744/einstein_journal/2022AO5587. eCollection 2022.

DOI:10.31744/einstein_journal/2022AO5587
PMID:35649051
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9126608/
Abstract

OBJECTIVE

To evaluate the effects of combining topiramate, bupropion and naltrexone in obesity-induced rats on their weight and subcutaneous adipose tissue.

METHODS

A total of 40 male Wistar rats were induced to obesity for 8 weeks and the animals were divided into 8 groups: Ctr - control, G0 - Sham, G1 - oral saline solution (1.0mL/day), G2 - topiramate (20.0mg/kg) and bupropion (5.0mg/kg), G3 - naltrexone (20.0mg/kg), G4 - topiramate (20.0mg/kg), G5 - bupropion (5.0mg/kg) and G6 - topiramate (20.0mg/kg), bupropion (5.0mg/kg) and naltrexone (20.0mg/kg). During the experiment, all animals were weighed weekly. After 30 days of treatment animals were euthanized and their skin fragments were processed and stained with hematoxylin and eosin for morphological, morphometric and biochemical analyzes.

RESULTS

The only group that presented a decrease in the volume of subcutaneous adipose tissue was G3, but this decrease was not significant when compared with the other groups. The G4, the G5 and the G6 presented increased adipose tissue volume. Data showed that until the eighth week all animals increased their weight by approximately 50%. After treatment animals of all groups, except G3, increased their weight from 4% to 9% approximately. The G3 was the only group that lost weight, but this decrease was not significant.

CONCLUSION

The medicines studied were not efficient in reducing weight in obese rats. However, it should be considered that 30-day treatment period is not enough to observe the stronger effects of these drugs.

摘要

目的

评估托吡酯、安非他酮和纳曲酮联合应用于肥胖诱导大鼠对其体重和皮下脂肪组织的影响。

方法

将 40 只雄性 Wistar 大鼠诱导肥胖 8 周,将动物分为 8 组:Ctr-对照组、G0-假手术组、G1-口服生理盐水(1.0mL/天)、G2-托吡酯(20.0mg/kg)和安非他酮(5.0mg/kg)、G3-纳曲酮(20.0mg/kg)、G4-托吡酯(20.0mg/kg)、G5-安非他酮(5.0mg/kg)和 G6-托吡酯(20.0mg/kg)、安非他酮(5.0mg/kg)和纳曲酮(20.0mg/kg)。在实验过程中,每周对所有动物进行称重。治疗 30 天后,动物被安乐死,其皮肤片段用苏木精和伊红染色进行形态学、形态计量学和生化分析。

结果

只有 G3 组皮下脂肪组织体积减少,但与其他组相比无显著差异。G4、G5 和 G6 组脂肪组织体积增加。数据显示,直到第 8 周,所有动物的体重都增加了约 50%。治疗后,除 G3 组外,所有组动物的体重增加了约 4%至 9%。G3 是唯一体重减轻的组,但这一减少无统计学意义。

结论

研究中的药物在减少肥胖大鼠体重方面效果不佳。然而,应该考虑到 30 天的治疗期不足以观察这些药物的更强效作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d40/9126608/5e1f5e1b3d21/2317-6385-eins-20-eAO5587-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d40/9126608/28d479a11727/2317-6385-eins-20-eAO5587-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d40/9126608/961a6f97af7d/2317-6385-eins-20-eAO5587-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d40/9126608/5e1f5e1b3d21/2317-6385-eins-20-eAO5587-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d40/9126608/28d479a11727/2317-6385-eins-20-eAO5587-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d40/9126608/961a6f97af7d/2317-6385-eins-20-eAO5587-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d40/9126608/5e1f5e1b3d21/2317-6385-eins-20-eAO5587-gf03.jpg

相似文献

1
Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats.托吡酯、安非他酮和纳曲酮单独或联合对肥胖大鼠皮下脂肪组织的影响。
Einstein (Sao Paulo). 2022 May 30;20:eAO5587. doi: 10.31744/einstein_journal/2022AO5587. eCollection 2022.
2
Gender-related issues in the pharmacology of new anti-obesity drugs.新型减肥药药理学中的性别相关问题。
Obes Rev. 2019 Mar;20(3):375-384. doi: 10.1111/obr.12805. Epub 2018 Dec 27.
3
Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.在啮齿动物模型中,胰淀素和安非他酮/纳曲酮对食物摄入和体重的影响具有交互作用。
Eur J Pharmacol. 2013 Jan 5;698(1-3):292-8. doi: 10.1016/j.ejphar.2012.11.010. Epub 2012 Nov 21.
4
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).纳曲酮缓释/安非他酮缓释片治疗体重和肥胖相关风险因素的随机、3 期临床试验(COR-II)。
Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309.
5
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.纳曲酮/安非他酮治疗肥胖的药物安全性评价。
Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28.
6
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.纳曲酮和安非他酮联合治疗肥胖症可减少总体和内脏脂肪量。
Diabetes Obes Metab. 2013 Sep;15(9):863-6. doi: 10.1111/dom.12095. Epub 2013 Apr 5.
7
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.纳曲酮/安非他酮用于治疗肥胖症:一种用于减肥的研究性联合药物疗法。
Pharmacol Res. 2014 Jun;84:1-11. doi: 10.1016/j.phrs.2014.04.004. Epub 2014 Apr 19.
8
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.氯卡色林、芬特明-托吡酯组合及纳曲酮-安非他酮组合用于减肥:区分这些药物的15分钟挑战
Int J Clin Pract. 2014 Dec;68(12):1401-5. doi: 10.1111/ijcp.12587.
9
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.联合疗法治疗肥胖症的安全性评估:聚焦于纳曲酮/安非他酮缓释剂和芬特明-托吡酯缓释剂
Expert Opin Drug Saf. 2017 Jan;16(1):27-39. doi: 10.1080/14740338.2017.1247807. Epub 2016 Oct 24.
10
Combination therapy with naltrexone and bupropion for obesity.纳曲酮与安非他酮联合治疗肥胖症。
Expert Opin Pharmacother. 2011 Aug;12(11):1813-26. doi: 10.1517/14656566.2011.591382. Epub 2011 Jun 21.

引用本文的文献

1
Adipose Tissue, Non-Communicable Diseases, and Physical Exercise: An Imperfect Triangle.脂肪组织、非传染性疾病与身体锻炼:一个不完美的三角形。
Int J Mol Sci. 2023 Dec 6;24(24):17168. doi: 10.3390/ijms242417168.

本文引用的文献

1
Current treatments for obesity.肥胖症的当前治疗方法。
Clin Med (Lond). 2019 May;19(3):205-212. doi: 10.7861/clinmedicine.19-3-205.
2
Current pharmacotherapies for obesity: A practical perspective.肥胖症的当前药物治疗:实用视角
J Am Assoc Nurse Pract. 2017 Oct;29(S1):S43-S52. doi: 10.1002/2327-6924.12519.
3
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.联合疗法治疗肥胖症的安全性评估:聚焦于纳曲酮/安非他酮缓释剂和芬特明-托吡酯缓释剂
Expert Opin Drug Saf. 2017 Jan;16(1):27-39. doi: 10.1080/14740338.2017.1247807. Epub 2016 Oct 24.
4
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.纳曲酮/安非他酮用于治疗肥胖症及伴有2型糖尿病的肥胖症。
Future Cardiol. 2016 Mar;12(2):129-38. doi: 10.2217/fca.15.79. Epub 2015 Dec 18.
5
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.纳曲酮/安非他酮用于治疗肥胖症:一种用于减肥的研究性联合药物疗法。
Pharmacol Res. 2014 Jun;84:1-11. doi: 10.1016/j.phrs.2014.04.004. Epub 2014 Apr 19.
6
Drug treatment of obesity.肥胖的药物治疗。
Psychiatr Clin North Am. 2011 Dec;34(4):871-80. doi: 10.1016/j.psc.2011.08.013.
7
Naltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults.纳曲酮缓释/安非他酮缓释片(Contrave):肥胖成年人减肥的新方法。
P T. 2011 May;36(5):255-62.
8
[Recent progress and novel perspectives on obesity pharmacotherapy].[肥胖症药物治疗的最新进展与新观点]
Arq Bras Endocrinol Metabol. 2010 Aug;54(6):516-29. doi: 10.1590/s0004-27302010000600003.
9
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.Contrave,一种安非他酮和纳曲酮的联合疗法,用于潜在治疗肥胖症。
Curr Opin Investig Drugs. 2009 Oct;10(10):1117-25.
10
Topiramate: a new potential pharmacological treatment for obesity.托吡酯:一种治疗肥胖症的新型潜在药物疗法。
Obes Res. 2004 Dec;12 Suppl:167S-73S. doi: 10.1038/oby.2004.284.